Peer Reviewed
Drug update

Using a combination of fluticasone/salmeterol in the treatment of COPD

Glenn Rice-mcdonald
Abstract
Fluticasone/salmeterol combination therapy (Seretide) should be considered in patients with moderate or severe COPD that is not adequately controlled by other therapy.
Key Points
    What is fluticasone/salmeterol combination therapy?

    Fluticasone/salmeterol (Seretide) is a combination of a long-acting beta2 agonist salmeterol and an inhaled corticosteroid fluticasone. It is available in a dry powder form (Seretide Accuhaler) or in a CFC-free inhaler (Seretide MDI). The indication to prescribe fluticasone/salmeterol has recently been extended from asthma to include chronic obstructive pulmonary disease (COPD).

Get full access
Subscribe for full access to all articles
Buy this article

Single article purchases are temporarily unavailable due to site maintenance.

If you would like to purchase an article during this time, please email us at [email protected] with the article details and we'll assist you directly. We'll also let you know when online purchasing is available again.

Thank you for your patience and understanding.

Already a subscriber?